GLG News by Physicians who Treat Acne (US)

 Study will be ridiculed.   1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.

This article is important in that it makes the public aware that they should avoid all unlicensed persons who re injecting any substance into their bodies. These especially include those injecting silicone mixtures. The public will become more aware and should have more confidence in licensed practitioners...

It is well known that millions of people in the US suffer from osteoporosis which leads directly to debilitating fractures.   Early diagnosis of osteoporosis and low bone mass will help prevent chronic pain and loss of independence.  Once diagnosed, treatment is readily available and...

Clinical trials have shown very similar efficacy and safety with both GSK's Rotarix and Merck's Rotateq.  With only two doses needed for Rotarix, pediatricians may opt for a simpler schedule.  Financial consideration will likely play the largest role in adopting the new vaccine.

 This article is important in that it lays to rest a misconception that long term repeated use of Botox ( Allergan) leads to decreased efficacy. Efficacy was maintained, and no neutralizing antibodies were found to Botox. This will reassure most users of Botox, and patients as well.

 This article is important in that it defined the incidence of serious skin reactions to the three common TNF antagonists- Enbrel, Humira, and Remicade. The incidence is relatively low in comparison to the numbers of patients treated. Any foreign protein has the potential for eliciting these reactions,...

Anacor's recent release of the data from their phase 2a study of AN 2728  for psoriasis were encouraging.  Over 69% actively treated plaques of psoriasis improved versus only 6% of placebo treated plaques. The study was limited by the short duration- only 28 days versus up to 16...

 This article is important in that it is one of the first to confirm what is  a widely held belief among many dematologists who treat many patients with psoriasis. Specifically that these patients suffer a higher rate of cardiovascular diseases, depression, malignancy, etc. This makes perfect...

Centocors new product- Ustekinumab /CNTO 1275 had impressive results in the recent PHOENIX trials and the application is under review at the FDA. The PASI score reductions are superior to the exiting agents such as Enbrel and Humira, and are comparable to those of the other Centocor product- Remicade...

(Directly pulled from the article.) Patients were randomly assigned to receive 2 doses, 45 or 90 mg, of subcutaneous ustekinumab, given 4 weeks apart and followed by treatments every 12 weeks.  Patients randomly assigned to receive 45 mg had a sustained PASI 75 (indicating an improvement in psoriatic...